- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
GENPHARMASEC has approved its financial results for the quarter ended June 30, 2025. Standalone revenue from operations reached Rs 12.11 Cr, with a profit after tax of Rs 1.56 Cr. On a consolidated basis, revenue stood at Rs 12.04 Cr, yielding a profit after tax of Rs 1.22 Cr. The company recently gained controlling interest in Derren Healthcare Pvt Ltd and established Clinigenome India Pvt Ltd as a new wholly-owned subsidiary, which expands its business activities and offers future growth prospects for shareholders.